Aurora News
Portfolio Company News
Roche Has Exercised Its Second Year Option to Screen More GPCR Targets With Norak's Transfluor® Technology

September 8 , 2004 - Research Triangle Park, NC.

Norak Biosciences, Inc. announced today that Roche has exercised its second year option to screen more of its G protein-coupled receptor (GPCR) targets of interest using Norak's Transfluor® technology.   The option was part of the agreement signed September 30, 2002 between Norak and Roche.   Under the terms of the agreement Norak will provide its Transfluor cell lines expressing GPCR targets of interest to Roche for use in a primary screen of its compound libraries.   Financial terms were not disclosed.

 Norak's Transfluor ® technology is a patented, universal GPCR drug discovery technology designed to be the most direct and accurate method for screening potential drug candidates against GPCR targets, whether known or orphan. Transfluor ® was licensed in 1999 by Norak from technology developed at Duke University Medical Center and represents the combined research into GPCR signaling pathways over several decades by Norak's scientific founders, Drs. Marc Caron, Robert Lefkowitz, and Larry Barak.

 About Norak:

Norak Biosciences, Inc., headquartered in Research Triangle Park, NC, is a private biotechnology company.   Norak is utilizing its proprietary Transfluor® technology to become a world leader in the discovery and development of drugs that regulate G protein-coupled receptors.   For more information about Norak Biosciences, Inc., please visit the Company's website at .


Contact Norak :        

Terry E. Willard

Executive Vice President              

Norak Biosciences, Inc.

7030 Kit Creek Road

Morrisville, NC 27560           

Phone: 919-248-8000 ext. 8804

Fax: 919-248-8033

Back to Portfolio News